Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
Takezako N, Kosugi H, Matsumoto M, Iida S, Ishikawa T, Kondo Y, Ando K, Miki H, Matsumura I, Sunami K, Teshima T, Iwasaki H, Onishi Y, Kizaki M, Izutsu K, Maruyama D, Tobinai K, Ghori R, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Suzuki K. Takezako N, et al. Among authors: kizaki m. Int J Hematol. 2020 Nov;112(5):640-649. doi: 10.1007/s12185-020-02953-3. Epub 2020 Sep 19. Int J Hematol. 2020. PMID: 32949374
Expression of activated integrin β7 in multiple myeloma patients.
Hosen N, Yoshihara S, Takamatsu H, Ri M, Nagata Y, Kosugi H, Shimomura Y, Hanamura I, Fuji S, Minauchi K, Kuroda J, Suzuki R, Nishimura N, Uoshima N, Nakamae H, Kawano Y, Mizuno I, Gomyo H, Suzuki K, Ozaki S, Nakamura S, Imai Y, Kizaki M, Negoro E, Handa H, Iida S. Hosen N, et al. Among authors: kizaki m. Int J Hematol. 2021 Jul;114(1):3-7. doi: 10.1007/s12185-021-03162-2. Epub 2021 May 17. Int J Hematol. 2021. PMID: 33999338
Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
Hosono N, Yokoyama H, Aotsuka N, Ando K, Iida H, Ishikawa T, Usuki K, Onozawa M, Kizaki M, Kubo K, Kuroda J, Kobayashi Y, Shimizu T, Chiba S, Nara M, Hata T, Hidaka M, Fujiwara SI, Maeda Y, Morita Y, Kusano M, Lu Q, Miyawaki S, Berrak E, Hasabou N, Naoe T. Hosono N, et al. Among authors: kizaki m. Int J Clin Oncol. 2021 Nov;26(11):2131-2141. doi: 10.1007/s10147-021-02006-7. Epub 2021 Aug 7. Int J Clin Oncol. 2021. PMID: 34363558 Free PMC article. Clinical Trial.
Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS).
Watanabe R, Murata M, Takayama N, Tokuhira M, Kizaki M, Okamoto S, Kawai Y, Watanabe K, Murakami H, Kikuchi M, Nakamura S, Ikeda Y. Watanabe R, et al. Among authors: kizaki m. Thromb Haemost. 1997 Apr;77(4):641-5. Thromb Haemost. 1997. PMID: 9134635 Clinical Trial.
Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.
Yasui H, Kobayashi M, Sato K, Kondoh K, Ishida T, Kaito Y, Tamura H, Handa H, Tsukune Y, Sasaki M, Komatsu N, Tanaka N, Tanaka J, Kizaki M, Kawamata T, Makiyama J, Yokoyama K, Imoto S, Tojo A, Imai Y. Yasui H, et al. Among authors: kizaki m. Int J Clin Oncol. 2021 Nov;26(11):2142-2150. doi: 10.1007/s10147-021-01991-z. Epub 2021 Jul 14. Int J Clin Oncol. 2021. PMID: 34259983
Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1).
Nakamura N, Maruyama D, Machida R, Ichinohe T, Takayama N, Ohba R, Ohmachi K, Imaizumi Y, Tokunaga M, Katsuya H, Yoshida I, Sunami K, Kurosawa M, Kubota N, Morimoto H, Kobayashi M, Kato H, Kameoka Y, Kagami Y, Kizaki M, Takeuchi K, Munakata W, Iida S, Nagai H. Nakamura N, et al. Among authors: kizaki m. Jpn J Clin Oncol. 2021 Jul 1;51(7):1059-1066. doi: 10.1093/jjco/hyab066. Jpn J Clin Oncol. 2021. PMID: 33959770 Free PMC article. Clinical Trial.
260 results